Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions

Gabriela Kramer-Marek, Jesse Gore, Murray Korc

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalCancer Letters
Volume341
Issue number2
DOIs
StatePublished - Dec 1 2013

Fingerprint

Molecular Imaging
Pancreatic Neoplasms
Molecular Probes
Investigational Therapies
Nanoparticles
Perfusion
Technology
Antibodies
Therapeutics
Neoplasms
Pancreatic Carcinoma

Keywords

  • Molecular imaging
  • PDAC
  • Ultrasonography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions. / Kramer-Marek, Gabriela; Gore, Jesse; Korc, Murray.

In: Cancer Letters, Vol. 341, No. 2, 01.12.2013, p. 132-138.

Research output: Contribution to journalArticle

Kramer-Marek, Gabriela ; Gore, Jesse ; Korc, Murray. / Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions. In: Cancer Letters. 2013 ; Vol. 341, No. 2. pp. 132-138.
@article{c7ddeb8c75e34df585ad98e81a29ae0f,
title = "Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions",
abstract = "Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.",
keywords = "Molecular imaging, PDAC, Ultrasonography",
author = "Gabriela Kramer-Marek and Jesse Gore and Murray Korc",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.canlet.2013.08.008",
language = "English",
volume = "341",
pages = "132--138",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions

AU - Kramer-Marek, Gabriela

AU - Gore, Jesse

AU - Korc, Murray

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

AB - Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

KW - Molecular imaging

KW - PDAC

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=84887148407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887148407&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.08.008

DO - 10.1016/j.canlet.2013.08.008

M3 - Article

C2 - 23941833

AN - SCOPUS:84887148407

VL - 341

SP - 132

EP - 138

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -